Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation
- PMID: 22790906
- DOI: 10.1007/s10620-012-2306-1
Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation
Abstract
Background: The present study evaluated performance characteristics of liver stiffness measurement (LSM) by FibroScan in patients with different stages of nonalcoholic fatty liver disease (NAFLD).
Patients and methods: A total of 307 subjects (120 NAFLD, 85 NAFLD related cirrhosis, and 102 healthy controls) were studied.
Results: In NAFLD patients, LSM had significant correlation with fibrosis (r = 0.68, p < 0.001), and increased progressively with increasing fibrosis (p < 0.001). However, the difference between stage 1 and stage 2 fibrosis was not significant (p = 0.07). The LSM in NAFLD without fibrosis and healthy controls was similar (p = 0.37). The areas under receiver-operating characteristics (AUROC) curve of LSM for stages ≥1, ≥2, ≥3, and 4 were 0.82, 0.85, 0.94, and 0.96, respectively. The best LSM (kPa) cut-offs for fibrosis stages ≥1, ≥2, ≥3 and 4 were 6.1, 7.0, 9.0, and 11.8, respectively. The negative predictive value of LSM for excluding advanced fibrosis was 95%. For advanced fibrosis, the AUROC curve of LSM was 0.94, followed by FIB-4 (0.75), BARD score (0.68), NAFLD fibrosis score (0.66), and aspartate platelet ratio index (0.60). In multivariate analysis, LSM was the only independent predictor of advanced fibrosis (odds ratio 1.47). In patients with NAFLD cirrhosis, LSM correlated significantly with Child-Pugh score (r = 0.40, p < 0.001), serum bilirubin (r = 0.34, p = 0.02), and grades of esophageal varices (r = 0.23, p = 0.04).
Conclusion: LSM is a useful tool for evaluation of patients with NAFLD, and is the best among other non-invasive predictors of liver fibrosis.
Similar articles
-
Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.Clin Gastroenterol Hepatol. 2019 Jan;17(1):156-163.e2. doi: 10.1016/j.cgh.2018.04.043. Epub 2018 Apr 26. Clin Gastroenterol Hepatol. 2019. PMID: 29705261 Free PMC article.
-
[Diagnostic value of liver stiffness measurement for the evaluation of liver fibrosis in nonalcoholic fatty liver].Zhonghua Gan Zang Bing Za Zhi. 2020 Jul 20;28(7):567-572. doi: 10.3760/cma.j.cn501113-20190302-00065. Zhonghua Gan Zang Bing Za Zhi. 2020. PMID: 32791791 Chinese.
-
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD.Clin Gastroenterol Hepatol. 2023 May;21(5):1293-1302.e5. doi: 10.1016/j.cgh.2022.06.013. Epub 2022 Jul 14. Clin Gastroenterol Hepatol. 2023. PMID: 35842119
-
Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.Hepatology. 2017 Nov;66(5):1486-1501. doi: 10.1002/hep.29302. Epub 2017 Sep 26. Hepatology. 2017. PMID: 28586172 Review.
-
Liver stiffness is associated with all-cause mortality in patients with NAFLD: A systematic review and meta-analysis.Liver Int. 2023 Dec;43(12):2604-2610. doi: 10.1111/liv.15742. Epub 2023 Sep 19. Liver Int. 2023. PMID: 37724792 Review.
Cited by
-
Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).J Clin Exp Hepatol. 2023 Mar-Apr;13(2):273-302. doi: 10.1016/j.jceh.2022.11.014. Epub 2022 Dec 7. J Clin Exp Hepatol. 2023. PMID: 36950481 Free PMC article. Review.
-
Correlation of Serum Transaminase Levels with Liver Fibrosis Assessed by Transient Elastography in Vietnamese Patients with Nonalcoholic Fatty Liver Disease.Int J Gen Med. 2021 Apr 16;14:1349-1355. doi: 10.2147/IJGM.S309311. eCollection 2021. Int J Gen Med. 2021. PMID: 33889015 Free PMC article.
-
NAFLD in children: new genes, new diagnostic modalities and new drugs.Nat Rev Gastroenterol Hepatol. 2019 Sep;16(9):517-530. doi: 10.1038/s41575-019-0169-z. Epub 2019 Jul 5. Nat Rev Gastroenterol Hepatol. 2019. PMID: 31278377 Review.
-
A Pilot Study on the Effect of Anti-Thrombopoietin Antibody on Platelet Count in Patients with Type 2 Diabetes.Molecules. 2020 Apr 4;25(7):1667. doi: 10.3390/molecules25071667. Molecules. 2020. PMID: 32260359 Free PMC article.
-
Prevalence and risk factors for non-alcoholic fatty liver in children and youth with obesity.BMC Pediatr. 2017 Apr 26;17(1):113. doi: 10.1186/s12887-017-0867-z. BMC Pediatr. 2017. PMID: 28446162 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical